Lupin Share Price
- All
- News
-
Lupin Falls After US FDA Inspects Goa Facility With Seven Observations
Lupin shares have so far this year fallen 2.73 per cent, sharply underperforming the benchmark Sensex which has advanced 23.6 per cent.
-
Nifty Seen Opening Below 17,500; Wipro, Lupin In Focus
Market Live Updates: Foreign institutional investors bought shares worth Rs 1,553 crore on Friday while domestic institutional investors sold shares worth Rs 1,398 crore.
-
Lupin Receives Tentative Nod For Anti-Seizure Drug; Stock Edges Higher
"The company (Lupin) has received tentative approval from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Brivaracetam Tablets," Lupin said
-
Lupin Gains On Receiving US FDA Nod To Launch Drug For Onychomycosis
Lupin received approval to launch Tavaborole Topical Solution, 5 per cent in United States (US) from the United States Food and Drug Administration (FDA).
-
Lupin Gains Nearly 1% As Subsidiary Gets New Drug Approval
The USFDA approved Lupin's US-based arm's supplemental new drug application (sNDA) to expand the use of Solosec for treating trichomoniasis in adults, Lupin said
-
Stocks To Watch: Dixon Technologies, Sobha Ltd, Lupin, Bandhan Bank, NMDC
The domestic stock markets are likely to open in the green after a day's paused due to positive cues from across the global markets.
-
Dr Reddy's Soars To Record High After Drug Maker Settles Patent Litigation In US
The Nifty Pharma index - which captures the performance of 10 drug makers in the country, including Dr Reddy's, Lupin, Cipla and Sun Pharma - jumped as much as 3.66 per cent.
-
Buy Firstsource Solutions, Lupin Shares, Says Choice Broking
Choice Broking has a "buy" call on Firstsource Solutions for a target price of Rs 54.50 with stop loss at Rs 49.25.
-
Lupin Profit At Rs 266 Crore In September Quarter, Misses Analysts' Estimates
Net profit was 266 crore ($36.00 million) in the quarter ended September 30, compared with a profit of Rs 455 crore a year earlier, Lupin said.
-
Lupin's Market Value Falls By Nearly Rs 5,500 Crore In One Day. Here Is Why
North America sales at Lupin slumped 13 per cent in the fourth quarter, dragging down net profit to Rs 380 crore from Rs 748 crore a year earlier.
-
Pharma Stocks Hit After Trump's 'Getting Away With Murder' Comment
Dr Reddy's Laboratories, Sun Pharmaceutical Industries and Lupin were the most hit, suffering losses of up to 3 per cent.
-
Sensex jumps 175 points; ONGC, Lupin lead
Oil and Natural Gas Corp rose 4 per cent after CLSA upgraded the stock to "buy" from "outperform", citing prospect of a 20 per cent upside to its share prices on positive factors such as the continuing hikes in monthly diesel prices and the recent doubling of gas prices.
-
Lupin falls over 4% on Credit Suisse downgrade
Drug maker Lupin fell over 4 per cent on Monday after global investment bank Credit Suisse downgraded the stocks to "neutral" from "outperform," citing unfavourable risk-reward. Credit Suisse' 12-month price target on the stock is Rs 755, which indicates the stock may already have hit its top.
-
Drug makers gain; not too hurt by pricing cap
Shares in pharmaceutical companies gained despite a recommendation by a ministry panel to cap drug prices given the proposal is seen as less hurtful than expected.
-
Lupin allots equity shares
Ajay Singh, director of SpiceJet, says a 10 per cent service tax imposed on domestic air travel in the Budget would mean an increase in air ticket prices by about Rs 350-400 given that the average economy fair is between Rs 3500-4000.
-
Lupin Falls After US FDA Inspects Goa Facility With Seven Observations
Lupin shares have so far this year fallen 2.73 per cent, sharply underperforming the benchmark Sensex which has advanced 23.6 per cent.
-
Nifty Seen Opening Below 17,500; Wipro, Lupin In Focus
Market Live Updates: Foreign institutional investors bought shares worth Rs 1,553 crore on Friday while domestic institutional investors sold shares worth Rs 1,398 crore.
-
Lupin Receives Tentative Nod For Anti-Seizure Drug; Stock Edges Higher
"The company (Lupin) has received tentative approval from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Brivaracetam Tablets," Lupin said
-
Lupin Gains On Receiving US FDA Nod To Launch Drug For Onychomycosis
Lupin received approval to launch Tavaborole Topical Solution, 5 per cent in United States (US) from the United States Food and Drug Administration (FDA).
-
Lupin Gains Nearly 1% As Subsidiary Gets New Drug Approval
The USFDA approved Lupin's US-based arm's supplemental new drug application (sNDA) to expand the use of Solosec for treating trichomoniasis in adults, Lupin said
-
Stocks To Watch: Dixon Technologies, Sobha Ltd, Lupin, Bandhan Bank, NMDC
The domestic stock markets are likely to open in the green after a day's paused due to positive cues from across the global markets.
-
Dr Reddy's Soars To Record High After Drug Maker Settles Patent Litigation In US
The Nifty Pharma index - which captures the performance of 10 drug makers in the country, including Dr Reddy's, Lupin, Cipla and Sun Pharma - jumped as much as 3.66 per cent.
-
Buy Firstsource Solutions, Lupin Shares, Says Choice Broking
Choice Broking has a "buy" call on Firstsource Solutions for a target price of Rs 54.50 with stop loss at Rs 49.25.
-
Lupin Profit At Rs 266 Crore In September Quarter, Misses Analysts' Estimates
Net profit was 266 crore ($36.00 million) in the quarter ended September 30, compared with a profit of Rs 455 crore a year earlier, Lupin said.
-
Lupin's Market Value Falls By Nearly Rs 5,500 Crore In One Day. Here Is Why
North America sales at Lupin slumped 13 per cent in the fourth quarter, dragging down net profit to Rs 380 crore from Rs 748 crore a year earlier.
-
Pharma Stocks Hit After Trump's 'Getting Away With Murder' Comment
Dr Reddy's Laboratories, Sun Pharmaceutical Industries and Lupin were the most hit, suffering losses of up to 3 per cent.
-
Sensex jumps 175 points; ONGC, Lupin lead
Oil and Natural Gas Corp rose 4 per cent after CLSA upgraded the stock to "buy" from "outperform", citing prospect of a 20 per cent upside to its share prices on positive factors such as the continuing hikes in monthly diesel prices and the recent doubling of gas prices.
-
Lupin falls over 4% on Credit Suisse downgrade
Drug maker Lupin fell over 4 per cent on Monday after global investment bank Credit Suisse downgraded the stocks to "neutral" from "outperform," citing unfavourable risk-reward. Credit Suisse' 12-month price target on the stock is Rs 755, which indicates the stock may already have hit its top.
-
Drug makers gain; not too hurt by pricing cap
Shares in pharmaceutical companies gained despite a recommendation by a ministry panel to cap drug prices given the proposal is seen as less hurtful than expected.
-
Lupin allots equity shares
Ajay Singh, director of SpiceJet, says a 10 per cent service tax imposed on domestic air travel in the Budget would mean an increase in air ticket prices by about Rs 350-400 given that the average economy fair is between Rs 3500-4000.
